Topiroxostat, a novel XO inhibitor, is attracting increasing attention because of its potential to decrease urinary albumin excretion in hyperuricemic patients with stage 3 chronic kidney disease (CKD) (Hosoya et al. The gene discussed is ALB; the disease is chronic kidney disease.